Patents by Inventor Edward G. Hayman

Edward G. Hayman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRUS PURIFICATION AND FORMULATION PROCESS
    Publication number: 20230122337
    Abstract: Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 20, 2023
    Applicant: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC
    Inventors: JOHN J. VICALVI, JR., EDWARD G. HAYMAN, JOSEPH MAKOWIECKI
  • VIRUS PURIFICATION AND FORMULATION PROCESS
    Publication number: 20190136206
    Abstract: Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Applicant: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: JOHN J. VICALVI, JR., EDWARD G. HAYMAN, JOSEPH MAKOWIECKI
  • Virus purification and formulation process
    Patent number: 10196615
    Abstract: Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: February 5, 2019
    Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: John J. Vicalvi, Jr., Edward G. Hayman, Joseph Makowiecki
  • High yield yellow fever virus strain with increased propagation in cells
    Patent number: 9655960
    Abstract: The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: May 23, 2017
    Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: Cynthia K. Lee, Thomas P. Monath, Patrick M. Guertin, Edward G. Hayman
  • VIRUS PURIFICATION AND FORMULATION PROCESS
    Publication number: 20160264943
    Abstract: Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Inventors: John J. VICALVI, Edward G. Hayman, Joseph Makowiecki
  • VIRUS PURIFICATION AND FORMULATION PROCESS
    Publication number: 20150210986
    Abstract: Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus. The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
    Type: Application
    Filed: August 16, 2013
    Publication date: July 30, 2015
    Inventors: John J. Vicalvi, JR., Edward G. Hayman, Joseph Makowiecki
  • HIGH YIELD YELLOW FEVER VIRUS STRAIN WITH INCREASED PROPAGATION IN CELLS
    Publication number: 20140322270
    Abstract: The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: CYNTHIA K. LEE, THOMAS P. MONATH, PATRICK M. GUERTIN, EDWARD G. HAYMAN
  • High yield yellow fever virus strain with increased propagation in cells
    Patent number: 8741312
    Abstract: The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: June 3, 2014
    Assignee: GE Healthcare Bio-Sciences Corp.
    Inventors: Cynthia K. Lee, Thomas P. Monath, Patrick M. Guertin, Edward G. Hayman
  • HIGH YIELD YELLOW FEVER VIRUS STRAIN WITH INCREASED PROPAGATION IN CELLS
    Publication number: 20110287519
    Abstract: The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.
    Type: Application
    Filed: January 25, 2011
    Publication date: November 24, 2011
    Applicant: Xcellerex, Inc.
    Inventors: Cynthia K. LEE, Thomas P. MONATH, Patrick M. GUERTIN, Edward G. HAYMAN
  • Peptides in cell detachment and aggregation
    Patent number: 4988621
    Abstract: A method of using synthetic cell attachment-promoting peptides from fibronectin to detach cultured cells from the substratum is described.
    Type: Grant
    Filed: December 10, 1987
    Date of Patent: January 29, 1991
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Edward G. Hayman, Michael D. Pierschbacher
  • Use of peptides in control of cell attachment and detachment
    Patent number: 4879237
    Abstract: A method of using synthetic cell attachment-promoting peptides from fibronectin to detach cultured cells from the substratum is described.
    Type: Grant
    Filed: May 24, 1985
    Date of Patent: November 7, 1989
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Eric I. Rudslahti, Edward G. Hayman, Michael D. Pierschbacher